DK3554554T3 - Exon-overspringnings-oligomerkonjugat til muskeldystrofi - Google Patents
Exon-overspringnings-oligomerkonjugat til muskeldystrofi Download PDFInfo
- Publication number
- DK3554554T3 DK3554554T3 DK17832405.9T DK17832405T DK3554554T3 DK 3554554 T3 DK3554554 T3 DK 3554554T3 DK 17832405 T DK17832405 T DK 17832405T DK 3554554 T3 DK3554554 T3 DK 3554554T3
- Authority
- DK
- Denmark
- Prior art keywords
- exon
- muscular dystrophy
- oligomer conjugate
- skipping oligomer
- skipping
- Prior art date
Links
- 201000006938 muscular dystrophy Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662436199P | 2016-12-19 | 2016-12-19 | |
| US201762443481P | 2017-01-06 | 2017-01-06 | |
| US201762479177P | 2017-03-30 | 2017-03-30 | |
| US201762562119P | 2017-09-22 | 2017-09-22 | |
| PCT/US2017/066351 WO2018118627A1 (en) | 2016-12-19 | 2017-12-14 | Exon skipping oligomer conjugates for muscular dystrophy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3554554T3 true DK3554554T3 (da) | 2022-11-07 |
Family
ID=61006319
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17832405.9T DK3554554T3 (da) | 2016-12-19 | 2017-12-14 | Exon-overspringnings-oligomerkonjugat til muskeldystrofi |
| DK22180767.0T DK4122497T3 (da) | 2016-12-19 | 2017-12-14 | Exonskipping-oligomerkonjugater til muskeldystrofi |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK22180767.0T DK4122497T3 (da) | 2016-12-19 | 2017-12-14 | Exonskipping-oligomerkonjugater til muskeldystrofi |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US11382981B2 (da) |
| EP (2) | EP4122497B1 (da) |
| JP (2) | JP7125940B2 (da) |
| KR (2) | KR102639633B1 (da) |
| CN (2) | CN117298290A (da) |
| AU (1) | AU2017382741A1 (da) |
| BR (1) | BR112019012651A2 (da) |
| CA (1) | CA3046801A1 (da) |
| CO (1) | CO2019007398A2 (da) |
| DK (2) | DK3554554T3 (da) |
| ES (1) | ES2929498T3 (da) |
| FI (1) | FI4122497T3 (da) |
| HR (1) | HRP20221316T1 (da) |
| HU (1) | HUE060065T2 (da) |
| IL (2) | IL267245B2 (da) |
| LT (2) | LT4122497T (da) |
| MD (1) | MD3554554T2 (da) |
| MX (1) | MX2019006989A (da) |
| NZ (1) | NZ755422A (da) |
| PL (1) | PL3554554T3 (da) |
| PT (1) | PT3554554T (da) |
| RS (1) | RS63705B1 (da) |
| SA (1) | SA519402143B1 (da) |
| SG (1) | SG10202100491QA (da) |
| SI (1) | SI3554554T1 (da) |
| TW (1) | TWI780095B (da) |
| WO (1) | WO2018118627A1 (da) |
| ZA (1) | ZA201903940B (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
| BR122022014984B1 (pt) | 2016-05-24 | 2024-03-05 | Sarepta Therapeutics, Inc | Compostos oligômeros morfolino fosforodiamidato |
| MA45362A (fr) | 2016-05-24 | 2019-04-10 | Sarepta Therapeutics Inc | Procédés de préparation d'oligomères morpholino de phosphorodiamidate |
| CN117298290A (zh) * | 2016-12-19 | 2023-12-29 | 萨勒普塔医疗公司 | 用于肌肉萎缩症的外显子跳跃寡聚体缀合物 |
| GB201821269D0 (en) | 2018-12-28 | 2019-02-13 | Nippon Shinyaku Co Ltd | Myostatin signal inhibitor |
| AU2020244803A1 (en) * | 2019-03-28 | 2021-11-18 | Sarepta Therapeutics, Inc. | Methods for treating muscular dystrophy with casimersen |
| WO2020214763A1 (en) * | 2019-04-18 | 2020-10-22 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
| WO2020257489A1 (en) * | 2019-06-19 | 2020-12-24 | Sarepta Therapeutics, Inc. | Methods for treating muscular dystrophy |
| CA3165961A1 (en) | 2019-12-26 | 2021-07-01 | Nippon Shinyaku Co., Ltd. | Antisense nucleic acid that induces skipping of exon 50 |
| CN115210376A (zh) | 2020-02-28 | 2022-10-18 | 日本新药株式会社 | 诱导外显子51的跳读的反义核酸 |
| EP4168425A4 (en) * | 2020-06-17 | 2024-06-19 | Stealth Biotherapeutics Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULAR DYSTROPHY |
| CA3216839A1 (en) * | 2021-04-30 | 2022-11-03 | Sarepta Therapeutics, Inc. | Treatment methods for muscular dystrophy |
| CN117940564A (zh) | 2021-06-23 | 2024-04-26 | 日本新药株式会社 | 反义低聚物的组合 |
| CN118201606A (zh) | 2021-07-08 | 2024-06-14 | 日本新药株式会社 | 肾毒性减轻剂 |
| TW202337473A (zh) | 2021-07-08 | 2023-10-01 | 日商日本新藥股份有限公司 | 腎毒性減輕劑 |
| CA3225573A1 (en) | 2021-07-08 | 2023-01-12 | Nippon Shinyaku Co., Ltd. | Precipitation suppressing agent |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH445129A (fr) | 1964-04-29 | 1967-10-15 | Nestle Sa | Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé |
| US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| US3453257A (en) | 1967-02-13 | 1969-07-01 | Corn Products Co | Cyclodextrin with cationic properties |
| US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
| US3453259A (en) | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| JP2528107B2 (ja) | 1985-03-15 | 1996-08-28 | サマ−トン，ジエ−ムス | ポリヌクレオチド測定試薬と方法 |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| WO1994002595A1 (en) | 1992-07-17 | 1994-02-03 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of animal diseases |
| CN1123038A (zh) | 1993-05-11 | 1996-05-22 | 北卡罗来纳大学查珀尔希尔分校 | 阻止异常剪接的反义寡核苷酸及其使用方法 |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
| US7572582B2 (en) | 1997-09-12 | 2009-08-11 | Exiqon A/S | Oligonucleotide analogues |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| WO1999042091A2 (en) | 1998-02-19 | 1999-08-26 | Massachusetts Institute Of Technology | Use of polycations as endosomolytic agents |
| US6683173B2 (en) | 1998-04-03 | 2004-01-27 | Epoch Biosciences, Inc. | Tm leveling methods |
| US6210892B1 (en) | 1998-10-07 | 2001-04-03 | Isis Pharmaceuticals, Inc. | Alteration of cellular behavior by antisense modulation of mRNA processing |
| JP2000125448A (ja) | 1998-10-14 | 2000-04-28 | Yazaki Corp | 電気接続箱 |
| JP2000256547A (ja) | 1999-03-10 | 2000-09-19 | Sumitomo Dow Ltd | 耐熱性プラスチックカード用樹脂組成物 |
| US7084125B2 (en) | 1999-03-18 | 2006-08-01 | Exiqon A/S | Xylo-LNA analogues |
| ES2283298T3 (es) | 1999-05-04 | 2007-11-01 | Santaris Pharma A/S | Analogos de l-ribo-lna. |
| JP2000325085A (ja) | 1999-05-21 | 2000-11-28 | Masafumi Matsuo | デュシェンヌ型筋ジストロフィー治療剤 |
| US7070807B2 (en) | 1999-12-29 | 2006-07-04 | Mixson A James | Branched histidine copolymers and methods for using same |
| WO2001047496A1 (en) | 1999-12-29 | 2001-07-05 | Mixson A James | Histidine copolymer and methods for using same |
| US6653467B1 (en) | 2000-04-26 | 2003-11-25 | Jcr Pharmaceutical Co., Ltd. | Medicament for treatment of Duchenne muscular dystrophy |
| US6727355B2 (en) | 2000-08-25 | 2004-04-27 | Jcr Pharmaceuticals Co., Ltd. | Pharmaceutical composition for treatment of Duchenne muscular dystrophy |
| EP1191097A1 (en) | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
| JP2005514005A (ja) | 2001-09-04 | 2005-05-19 | エクシコン エ／エス | 新規のｌｎａ組成物およびその使用 |
| KR100464261B1 (ko) | 2002-01-24 | 2005-01-03 | 주식회사 파나진 | Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법 |
| KR20030084444A (ko) | 2002-04-26 | 2003-11-01 | 주식회사 파나진 | Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법 |
| US7569575B2 (en) | 2002-05-08 | 2009-08-04 | Santaris Pharma A/S | Synthesis of locked nucleic acid derivatives |
| WO2004043977A2 (en) | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | 2’-fluoro substituted oligomeric compounds and compositions for use in gene modulations |
| CA3001404C (en) | 2002-11-25 | 2020-07-28 | Masafumi Matsuo | Ena nucleic acid pharmaceuticals capable of modifying splicing of mrna precursors |
| AU2003225410A1 (en) | 2003-03-21 | 2004-10-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| US7211668B2 (en) | 2003-07-28 | 2007-05-01 | Panagene, Inc. | PNA monomer and precursor |
| DE602005026386D1 (de) | 2004-06-28 | 2011-03-31 | Univ Western Australia | Antisense-oligonukleotide zur induktion von exon-skipping sowie verfahren zur verwendung davon |
| KR20080031164A (ko) | 2005-04-22 | 2008-04-08 | 아카데미슈 지켄후이스 라이덴 | ＳＲ 단백질의 결합의 방해에 의해 그리고 이차 ＲＮＡ구조의 방해에 의한 ｐｒｅ－ｍＲＮＡ에서 엑손 인식의조절 |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| EP1951872A2 (en) | 2005-11-10 | 2008-08-06 | The University of North Carolina at Chapel Hill | Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease |
| JP3151554U (ja) | 2006-05-17 | 2009-07-02 | スヴェトラナ アナトレフナ ソコロヴァ | 輸送手段 |
| US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| US20090099066A1 (en) | 2007-06-29 | 2009-04-16 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
| CN101790385A (zh) | 2007-07-12 | 2010-07-28 | 普罗森那技术公司 | 用于使化合物靶向多种选定器官、组织或肿瘤细胞的分子 |
| PT2203173E (pt) | 2007-10-26 | 2016-03-15 | Academisch Ziekenhuis Leiden | Resumo |
| US8299206B2 (en) | 2007-11-15 | 2012-10-30 | Avi Biopharma, Inc. | Method of synthesis of morpholino oligomers |
| CA2884340C (en) | 2007-11-15 | 2017-07-25 | Sarepta Therapeutics, Inc. | Method of synthesis of morpholino oligomers |
| US8076476B2 (en) | 2007-11-15 | 2011-12-13 | Avi Biopharma, Inc. | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits |
| WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| US8084601B2 (en) | 2008-09-11 | 2011-12-27 | Royal Holloway And Bedford New College Royal Holloway, University Of London | Oligomers |
| CN102203253B (zh) | 2008-10-24 | 2016-04-06 | 萨雷普塔治疗公司 | 用于dmd的多外显子跳跃组合物 |
| ES2562658T3 (es) | 2008-10-27 | 2016-03-07 | Biomarin Technologies B.V. | Procedimientos y medios para el salto eficiente del exón 45 en el pre-ARNm de la distrofia muscular de Duchenne |
| CN102282155B (zh) | 2008-12-02 | 2017-06-09 | 日本波涛生命科学公司 | 磷原子修饰的核酸的合成方法 |
| CN109576268A (zh) | 2009-04-10 | 2019-04-05 | 肌肉学研究协会 | 用于治疗疾病的三环dna反义寡核苷酸、组合物和方法 |
| AU2010239779A1 (en) | 2009-04-24 | 2011-11-17 | Prosensa Technologies B.V. | Oligonucleotide comprising an inosine for treating DMD |
| IN2012DN00720A (da) | 2009-07-06 | 2015-06-19 | Ontorii Inc | |
| CN102574888A (zh) | 2009-09-16 | 2012-07-11 | 株式会社启拉坚 | 用于rna及其衍生物的合成的新型保护基 |
| EP2499249B1 (en) | 2009-11-12 | 2018-08-08 | The University Of Western Australia | Antisense molecules and methods for treating pathologies |
| BR112012031363A2 (pt) | 2010-05-28 | 2021-10-26 | Sarepta Therapeutcs, Inc | Análogos de oligonucleotídeo tendo ligações intersubunidades modificadas e/ou grupos terminais. |
| TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
| DK2620428T3 (da) | 2010-09-24 | 2019-07-01 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
| JP2014507143A (ja) * | 2011-02-08 | 2014-03-27 | ザ シャーロット−メクレンバーグ ホスピタル オーソリティ ドゥーイング／ビジネス／アズ キャロライナズ ヘルスケア システム | アンチセンスオリゴヌクレオチド |
| US9161948B2 (en) * | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| JP6478632B2 (ja) | 2011-05-05 | 2019-03-06 | サレプタ セラピューティクス， インコーポレイテッド | ペプチドオリゴヌクレオチドコンジュゲート |
| US9607308B2 (en) | 2011-06-29 | 2017-03-28 | American Express Travel Related Services Company, Inc. | Spend based digital ad targeting and measurement |
| PT2581448E (pt) | 2011-10-13 | 2015-05-21 | Institut National De La Santé Et De La Rech Médicale (Inserm) | Dna triciclo-fosforotioato |
| US9944926B2 (en) | 2011-11-30 | 2018-04-17 | Sarepta Therapeutics, Inc. | Induced exon inclusion in spinal muscle atrophy |
| CN118207212A (zh) | 2011-12-28 | 2024-06-18 | 日本新药株式会社 | 反义核酸 |
| JP2015509922A (ja) | 2012-01-27 | 2015-04-02 | プロセンサ テクノロジーズ ビー．ブイ．Ｐｒｏｓｅｎｓａ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｂ．Ｖ． | デュシェンヌ型及びベッカー型筋ジストロフィーの治療のための改善された特徴を有するｒｎａ調節オリゴヌクレオチド |
| DE102012101676A1 (de) | 2012-02-29 | 2013-08-29 | Klaus-Dieter Rösler | Verfahren und Vorrichtung zum Bearbeiten von Formularen mit einer Datenverarbeitungsanlage |
| WO2014007620A2 (en) * | 2012-07-03 | 2014-01-09 | Prosensa Technologies B.V. | Oligonucleotide for the treatment of muscular dystrophy patients |
| DK2872485T3 (da) | 2012-07-13 | 2021-03-08 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
| WO2014012081A2 (en) | 2012-07-13 | 2014-01-16 | Ontorii, Inc. | Chiral control |
| EP2900835A4 (en) | 2012-09-27 | 2016-05-11 | Population Diagnotics Inc | METHODS AND COMPOSITIONS FOR DETECTING AND TREATING DEVELOPMENTAL DISORDERS |
| CN111440796A (zh) | 2012-12-20 | 2020-07-24 | 萨雷普塔医疗公司 | 用于治疗肌营养不良症的改良的外显子跳跃组合物 |
| US9856474B2 (en) * | 2013-01-16 | 2018-01-02 | Iowa State University Research Foundation, Inc. | Deep intronic target for splicing correction on spinal muscular atrophy gene |
| CN110066793A (zh) | 2013-03-14 | 2019-07-30 | 萨勒普塔医疗公司 | 用于治疗肌肉萎缩的外显子跳跃组合物 |
| NZ790263A (en) * | 2013-03-14 | 2023-07-28 | Sarepta Therapeutics Inc | Exon skipping compositions for treating muscular dystrophy |
| CN105307723A (zh) * | 2013-03-15 | 2016-02-03 | 萨勒普塔医疗公司 | 改进的用于治疗肌营养不良的组合物 |
| US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| EP3095460A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| KR20220106232A (ko) | 2014-01-16 | 2022-07-28 | 웨이브 라이프 사이언시스 리미티드 | 키랄 디자인 |
| US20150329609A1 (en) | 2014-03-03 | 2015-11-19 | Sujata Acharjee | Chimeric dystrophin proteins to treat dystrophinopathies |
| HUE042283T2 (hu) | 2014-03-12 | 2019-06-28 | Nippon Shinyaku Co Ltd | Antiszensz nukleinsav |
| ES2765463T3 (es) | 2014-06-17 | 2020-06-09 | Nippon Shinyaku Co Ltd | Acido nucleico antisentido para usar en el tratamiento de la distrofia muscular de Duchenne |
| US20160130567A1 (en) | 2014-11-02 | 2016-05-12 | Arcturus Therapeutics, Inc. | Messenger una molecules and uses thereof |
| MA43072A (fr) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| SG10201912902TA (en) | 2015-10-09 | 2020-02-27 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods thereof |
| JP2018530560A (ja) * | 2015-10-09 | 2018-10-18 | サレプタ セラピューティクス， インコーポレイテッド | デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法 |
| KR102329187B1 (ko) * | 2016-04-29 | 2021-11-22 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 인간 lmna를 표적화하는 올리고뉴클레오타이드 유사체 |
| MA45270A (fr) | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| MA45290A (fr) | 2016-05-04 | 2019-03-13 | Wave Life Sciences Ltd | Procédés et compositions d'agents biologiquement actifs |
| MX2019006879A (es) | 2016-12-19 | 2019-08-01 | Sarepta Therapeutics Inc | Conjugados de oligomeros de omision de exon para distrofia muscular. |
| CA3046793A1 (en) | 2016-12-19 | 2018-06-28 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| CN117298290A (zh) * | 2016-12-19 | 2023-12-29 | 萨勒普塔医疗公司 | 用于肌肉萎缩症的外显子跳跃寡聚体缀合物 |
-
2017
- 2017-12-14 CN CN202311010831.2A patent/CN117298290A/zh active Pending
- 2017-12-14 CN CN201780086303.1A patent/CN110337308B/zh active Active
- 2017-12-14 IL IL267245A patent/IL267245B2/en unknown
- 2017-12-14 HU HUE17832405A patent/HUE060065T2/hu unknown
- 2017-12-14 PL PL17832405.9T patent/PL3554554T3/pl unknown
- 2017-12-14 RS RS20221008A patent/RS63705B1/sr unknown
- 2017-12-14 JP JP2019531379A patent/JP7125940B2/ja active Active
- 2017-12-14 EP EP22180767.0A patent/EP4122497B1/en active Active
- 2017-12-14 MD MDE20191208T patent/MD3554554T2/ro unknown
- 2017-12-14 ES ES17832405T patent/ES2929498T3/es active Active
- 2017-12-14 BR BR112019012651A patent/BR112019012651A2/pt active Search and Examination
- 2017-12-14 LT LTEP22180767.0T patent/LT4122497T/lt unknown
- 2017-12-14 DK DK17832405.9T patent/DK3554554T3/da active
- 2017-12-14 PT PT178324059T patent/PT3554554T/pt unknown
- 2017-12-14 SI SI201731254T patent/SI3554554T1/sl unknown
- 2017-12-14 NZ NZ755422A patent/NZ755422A/en unknown
- 2017-12-14 LT LTEPPCT/US2017/066351T patent/LT3554554T/lt unknown
- 2017-12-14 KR KR1020197020409A patent/KR102639633B1/ko active IP Right Grant
- 2017-12-14 EP EP17832405.9A patent/EP3554554B1/en active Active
- 2017-12-14 KR KR1020237039425A patent/KR20240006023A/ko active Search and Examination
- 2017-12-14 FI FIEP22180767.0T patent/FI4122497T3/fi active
- 2017-12-14 WO PCT/US2017/066351 patent/WO2018118627A1/en unknown
- 2017-12-14 HR HRP20221316TT patent/HRP20221316T1/hr unknown
- 2017-12-14 MX MX2019006989A patent/MX2019006989A/es unknown
- 2017-12-14 AU AU2017382741A patent/AU2017382741A1/en active Pending
- 2017-12-14 US US16/469,104 patent/US11382981B2/en active Active
- 2017-12-14 CA CA3046801A patent/CA3046801A1/en active Pending
- 2017-12-14 DK DK22180767.0T patent/DK4122497T3/da active
- 2017-12-14 SG SG10202100491QA patent/SG10202100491QA/en unknown
- 2017-12-18 TW TW106144430A patent/TWI780095B/zh active
-
2019
- 2019-06-17 SA SA519402143A patent/SA519402143B1/ar unknown
- 2019-06-18 ZA ZA2019/03940A patent/ZA201903940B/en unknown
- 2019-07-10 CO CONC2019/0007398A patent/CO2019007398A2/es unknown
-
2022
- 2022-05-02 JP JP2022075930A patent/JP2022101695A/ja active Pending
- 2022-05-26 US US17/804,280 patent/US20220387601A1/en active Pending
-
2023
- 2023-07-05 IL IL304284A patent/IL304284A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3554553T3 (da) | Exon-overspringnings-oligomerkonjugat til muskeldystrofi | |
| DK3554554T3 (da) | Exon-overspringnings-oligomerkonjugat til muskeldystrofi | |
| ZA201905396B (en) | Trans-replicating rna | |
| IL257091B (en) | Targeted oligonucleotides | |
| MA42134A (fr) | Conjugués peptides/oligonucléotides | |
| DK3466976T3 (da) | Anti-her2-antistof-lægemiddelkonjugat | |
| DK3527574T3 (da) | Alvocidib-prodrugs, der har øget biotilgængelighed | |
| HK1255466A1 (zh) | 寡核苷酸綴合方法 | |
| GB201503408D0 (en) | Oligonucleotides | |
| ZA202001649B (en) | Rna molecules | |
| GB201504124D0 (en) | Oligonucleotides | |
| DK3385386T3 (da) | Biosyntetisk carrimycin-gencluster | |
| GB201518881D0 (en) | Mechanical device for amplifying relative displacement | |
| CL2016001202S1 (es) | Neumatico. | |
| MA49708A (fr) | Dérivés de dihétérocycle liés à cycloalkyle | |
| DK3134794T3 (da) | Taktfase-alignment | |
| DK3057373T3 (da) | Enkeltcelle-punkt-til-multipunkt-overførsel | |
| DK3237407T3 (da) | 3,5-diaminopyrazolkinasehæmmere | |
| ES1138606Y (es) | Medio agrupador para envases | |
| IT201600106459A1 (it) | Skistopper per attacchi da scialpinismo | |
| UA32332S (uk) | Вивіска для аптеки | |
| AU2015136V (en) | Sundarose Petunia sp. | |
| AU2015138V (en) | Sundasiro Petunia sp. | |
| AU2015137V (en) | Sundapin Petunia sp. | |
| UA32878S (uk) | Блок скоб |